In addition to addressing comorbidities associated with cardiovascular, renal, and metabolic conditions, the use of SGLT2 inhibitors and GLP-1 receptor agonists has been shown to be effective in patients with type 2 diabetes mellitus (55). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.